Year: 2024 | Month: July | Volume: 11 | Issue: 7 | Pages: 10-16
DOI: https://doi.org/10.52403/ijrr.20240702
hWJ-MSC Reduces IL-1β Gene Expression in Alzheimer's Rat Models
Nita Afriani1, Eryati Darwin1, Hirowati Ali2, Yuliarni Syafrita3
1Department of Histology, Faculty of Medicine, Andalas University, Jl. Perintis Kemerdekaan No.94, Padang, Indonesia
2Department of Biochemistry, Faculty of Medicine, Andalas University, Jl. Perintis Kemerdekaan No.94, Padang, Indonesia
3Department of Neurology, Faculty of Medicine, Andalas University, Jl. Perintis Kemerdekaan No. 94, Padang, Indonesia
Corresponding Author: Nita Afriani
ABSTRACT
Objective: This study aims to study effect of Wharton's Jelly MSCs regulate IL-1β gene expression and to evaluate the potential of these MSCs as an innovative therapy for Alzheimer's disease;
Method: This study was post test only control group design. Male Wistar rats were divided into three groups: Control, AlCl3, and AlCl3 + hWJ-MSC. AlCl3 (300 mg/kg/day) was administered orally for 5 days. hWJ-MSCs (1x106 cells) were injected intraperitoneally on day 11. Brain tissue RNA was isolated using TRIzol®, and cDNA synthesis was conducted. Gene expression was analyzed by real-time PCR;
Result: The results of this study showed that the average of IL-1β levels in Negative Control, Positive Control and Treatment were 0.536 ± 0.342, 0.804 ± 0.801, 0.694± 0.303;
Conclusion: Our study indicates that human Wharton's Jelly Mesenchymal Stem Cells (hWJ-MSCs) can reduce IL-1β levels in an Alzheimer's disease model, suggesting their potential to alleviate inflammation. Although the decrease was not statistically significant, these findings open new avenues for exploring hWJ-MSCs as a promising therapeutic option for Alzheimer's disease.
Keywords: Alzheimer, hWJ-MSC, IL-1β, AlCl3
[PDF Full Text]